Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.5843 http://scihub22266oqcxt.onion/10.18632/oncotarget.5843 C4747396!4747396 !26510913     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26510913 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26510913 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2015 ; 6 (38 ): 41146-61 Nephropedia Template TP {{tp|p=26510913 |t=2015. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth |pdf=|usr=}}{{26510913 }} gab.com Text Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26510913 #FOAvip Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumor-bearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models. Twit Text FOAVip Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26510913 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26510913 #FOAvip English Wikipedia <ref>{{Cite pmid|26510913 }}</ref> Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth #MMPMID26510913 Shukla SK ; Dasgupta A ; Mehla K ; Gunda V ; Vernucci E ; Souchek J ; Goode G ; King R ; Mishra A ; Rai I ; Nagarajan S ; Chaika NV ; Yu F ; Singh PK Oncotarget 2015[Dec]; 6 (38 ): 41146-61 PMID26510913 show ga Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product silibinin for its effectiveness in targeting pancreatic cancer aggressiveness and the cachectic properties of pancreatic cancer cells and tumors. Our results demonstrate that silibinin inhibits pancreatic cancer cell growth in a dose-dependent manner and reduces glycolytic activity of cancer cells. Our LC-MS/MS based metabolomics data demonstrates that silibinin treatment induces global metabolic reprogramming in pancreatic cancer cells. Silibinin treatment diminishes c-MYC expression, a key regulator of cancer metabolism. Furthermore, we observed reduced STAT3 signaling in silibinin-treated cancer cells. Overexpression of constitutively active STAT3 was sufficient to substantially revert the silibinin-induced downregulation of c-MYC and the metabolic phenotype. Our in vivo investigations demonstrate that silibinin reduces tumor growth and proliferation in an orthotopic mouse model of pancreatic cancer and prevents the loss of body weight and muscle. It also improves physical activity including grip strength and latency to fall in tumor-bearing mice. In conclusion, silibinin-induced metabolic reprogramming diminishes cell growth and cachectic properties of pancreatic cancer cells and animal models. |*Xenograft Model Antitumor Assays [MESH] |Animals [MESH] |Antioxidants/pharmacology [MESH] |Cachexia/etiology/metabolism/*prevention & control [MESH] |Cell Line [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation/drug effects [MESH] |Dose-Response Relationship, Drug [MESH] |Female [MESH] |Glycolysis/drug effects [MESH] |Humans [MESH] |Immunoblotting [MESH] |Interleukin-6/genetics/metabolism [MESH] |Metabolome/*drug effects [MESH] |Mice, Nude [MESH] |Pancreatic Neoplasms/complications/*drug therapy/metabolism [MESH] |Proto-Oncogene Proteins c-myc/genetics/metabolism [MESH] |Reverse Transcriptase Polymerase Chain Reaction [MESH] |STAT3 Transcription Factor/genetics/metabolism [MESH] |Signal Transduction/drug effects [MESH] |Silybin [MESH] |Silymarin/*pharmacology [MESH] |Tumor Burden/drug effects [MESH]Silibinin-mediated metabolic reprogramming attenuates pancreatic cance(epmc).pdf DeepDyve Pubget Overpricing